tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Abnormalities, Multiple D000015 13 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Acne Vulgaris D000152 35 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Akinetic Mutism D000405 1 associated lipids
Albuminuria D000419 18 associated lipids
Alopecia D000505 14 associated lipids
Alopecia Areata D000506 6 associated lipids
Alzheimer Disease D000544 76 associated lipids
Amenorrhea D000568 4 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Anemia D000740 21 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Anemia, Refractory D000753 3 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Aneurysm, Dissecting D000784 2 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Angioedema D000799 6 associated lipids
Anus Diseases D001004 3 associated lipids
Apraxias D001072 1 associated lipids
Arm Injuries D001134 1 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Arthritis, Juvenile D001171 8 associated lipids
Ascites D001201 25 associated lipids
Ataxia D001259 20 associated lipids
Ataxia Telangiectasia D001260 6 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Bacterial Infections D001424 21 associated lipids
Balanitis D001446 4 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Behcet Syndrome D001528 7 associated lipids
Biliary Fistula D001658 13 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Blepharitis D001762 4 associated lipids
Blindness D001766 6 associated lipids
Body Weight D001835 333 associated lipids
Bone Diseases D001847 4 associated lipids
Bradycardia D001919 13 associated lipids
Brain Diseases D001927 27 associated lipids
Brain Edema D001929 20 associated lipids
Bronchiolitis D001988 6 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Alessiani M et al. Adverse effects of FK 506 overdosage after liver transplantation. 1993 Transplant. Proc. pmid:7679825
Nishikawa K et al. Experimental studies of vascularized joint allografts in rats. 1994 Transplant. Proc. pmid:7513482
Demetris AJ et al. Pathologic observations in human allograft recipients treated with FK 506. 1990 Transplant. Proc. pmid:1689891
Kobayashi M et al. FK 506 assay past and present--characteristics of FK 506 ELISA. 1991 Transplant. Proc. pmid:1721258
Shapiro R et al. The side effects of FK 506 in humans. 1990 Transplant. Proc. pmid:1689892
Bechstein WO et al. Tacrolimus (FK 506) therapy is associated with a significant reduction in immunosuppressive treatment failures following primary liver transplantation. 1996 Transplant. Proc. pmid:8623211
Shapiro R et al. Outcome after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppression. 1998 Transplant. Proc. pmid:9636557
Okamoto M et al. Beneficial effect of multiple drug therapy including tacrolimus in clinical renal transplantation. 2000 Transplant. Proc. pmid:11119905
Chakkera HA et al. Genetic differences in Native Americans and tacrolimus dosing after kidney transplantation. 2013 Jan-Feb Transplant. Proc. pmid:23375287
Tian Ch et al. B- and T-lymphocyte attenuator/herpes virus entry mediator as early indicators for acute rejection following kidney transplantation. 2013 Jan-Feb Transplant. Proc. pmid:23375291
Ochiai M et al. Islet toxicity of FK506 measured in canine autografts. 1998 Transplant. Proc. pmid:9532224
Sahar G et al. Glucose metabolism in heart transplant recipients treated with FK506 or cyclosporine. 2003 Transplant. Proc. pmid:12644092
Ruiz MC et al. Effect of early versus delayed calcineurin inhibitor treatment on delayed graft function. 2003 Transplant. Proc. pmid:12644096
Vilalta R et al. Delayed graft function is reduced with antithymocyte globulin induction in pediatric kidney transplantation. 2009 Jul-Aug Transplant. Proc. pmid:19715923
Sgrosso JL et al. Tacrolimus pharmacokinetics in heart transplant. 2002 Transplant. Proc. pmid:11959225
Fraile P et al. Non-skin solid tumors as a cause of morbidity and mortality after liver transplantation. 2009 Jul-Aug Transplant. Proc. pmid:19715943
Roman A et al. Preliminary results of rescue therapy with tacrolimus and mycophenolate mofetil in lung transplanted patients with bronchiolitis obliterans. 2002 Transplant. Proc. pmid:11959227
Žilinská Z et al. Impact of Trough Levels of Tacrolimus on Kidney Function and Graft Survival in Short and Longer Periods After Renal Transplantation. 2016 Transplant. Proc. pmid:27788794
McCauley J et al. Cyclosporine and FK 506 induced inhibition of renal epithelial cell proliferation. 1991 Transplant. Proc. pmid:1721290
Ciancio G et al. Human donor bone marrow cells can enhance hyporeactivity in renal transplantation using maintenance FK 506 and OKT3 induction therapy. 1996 Transplant. Proc. pmid:8623473
McAlister VC et al. Cost of liver transplantation using tacrolimus. 1998 Transplant. Proc. pmid:9636611
Braun F et al. Primary tacrolimus immunosuppression in kidney recipients considered "higher immunologic risk". 2000 Transplant. Proc. pmid:11120281
Woodle ES et al. Corticosteroid withdrawal under tacrolimus primary and rescue therapy in renal transplantation: the Chicago experience. 1999 Transplant. Proc. pmid:10576053
Sathyan S et al. A case of recurrent immunotactoid glomerulopathy in an allograft treated with rituximab. 2009 Transplant. Proc. pmid:19917422
Kaminska D et al. Mycophenolate mofetil but not the type of calcineurin inhibitor (cyclosporine vs tacrolimus) influences the intragraft mRNA expression of cytokines in human kidney allograft biopsies by in situ RT-PCR analysis. 2005 Transplant. Proc. pmid:15848526
Marzoa-Rivas R et al. Conversion of heart transplant patients from standard to sustained-release tacrolimus requires a dosage increase. 2010 Transplant. Proc. pmid:20970591
Lodewijk L et al. Effect of liver regeneration on the pharmacokinetics of immunosuppressive drugs. 2009 Jan-Feb Transplant. Proc. pmid:19249561
Ohtsuka S et al. Effect of splenectomy on hamster-to-rat pancreas xenotransplantation. 1994 Transplant. Proc. pmid:7518109
Meiser BM et al. Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model. 1993 Transplant. Proc. pmid:7682363
O'Rourke M et al. Recovery of delayed-type hypersensitivity following liver transplantation. 1995 Transplant. Proc. pmid:7533369
Yu Y et al. Mutagenicity of the new immunosuppressive drugs, FK 506, and spergualin. 1993 Transplant. Proc. pmid:7682364
Gaweco AS et al. Common and sequential overexpression patterns of T-helper cytokines during acute (cellular) rejection, and correlation of proinflammatory cytokine expression with chronic (ductopenic) rejection of human liver allografts: a study under cyclosporine, FK 506, and quadruple BT 563 immunosuppression. 1995 Transplant. Proc. pmid:7533370
Fukuzawa M et al. Effect of FK 506 on CD4+ and CD8+ T-cell function in vivo. 1991 Transplant. Proc. pmid:1721321
Takaori K et al. Effects of FK 506 on in vivo immunity in comparison to cyclosporine. 1991 Transplant. Proc. pmid:1721322
Liu B et al. Single-center experience: tacrolimus and mycophenolate mofetil in early stage of kidney transplantation with liver dysfunction. 2003 Transplant. Proc. pmid:12591396
Nakamura K et al. Renal transplant recipient experiencing pneumatosis cystoides intestinalis: a case report. 2003 Transplant. Proc. pmid:12591410
Iwahori T et al. Pharmacokinetic differences between morning and evening administration of cyclosporine and tacrolimus therapy. 2005 Transplant. Proc. pmid:15919450
Takeuchi H et al. Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters. 2005 Transplant. Proc. pmid:15919452
Sarvary E et al. De novo Prograf versus de novo Advagraf: are trough level profile curves similar? Transplant. Proc. pmid:25131131
Funayama Y et al. Changes in cell adhesion molecules after small bowel transplantation in rats. 1995 Transplant. Proc. pmid:7533426
Paul AA et al. CMV retinitis and the use of FK 506. 1991 Transplant. Proc. pmid:1721354
Escartín A et al. Analysis of pig-MAP after small bowel transplantation in pigs. 1998 Transplant. Proc. pmid:9865377
Scantlebury VP et al. Outcome of kidney transplantation in African-Americans using tacrolimus. 1997 Transplant. Proc. pmid:9414906
Oğütmen B et al. Transforming growth factor-beta1, vascular endothelial growth factor, and bone morphogenic protein-7 expression in tacrolimus-induced nephrotoxicity in rats. 2006 Transplant. Proc. pmid:16549155
Branco KC et al. The impact of tacrolimus as rescue therapy in children using a double immunosuppressive regimen after heart transplantation. 2012 Transplant. Proc. pmid:23026625
Sánchez-Fructuoso AI et al. Daclizumab induction as an immunosuppressive regimen for renal transplant recipients from non-heart-beating donors. 2003 Transplant. Proc. pmid:12962759
Cotovio P et al. New-onset diabetes after transplantation: assessment of risk factors and clinical outcomes. 2013 Transplant. Proc. pmid:23622631
Valente G et al. Conversion from twice-daily to once-daily tacrolimus in stable liver transplant patients: effectiveness in a real-world setting. 2013 Transplant. Proc. pmid:23622676
Zhu Y et al. Prolongation of canine renal allograft survival by combining tacrolimus with antimetabolic agents. 1997 Feb-Mar Transplant. Proc. pmid:9123011
Nishimoto Y et al. Real-time monitoring for detecting rejection using strain gauge force transducers in porcine small bowel transplantation. 2004 Transplant. Proc. pmid:15050153
Miyazawa H et al. Graft immunomodulation by donor irradiation and recipient-specific bone marrow cells in rat small bowel transplantation. 2002 Transplant. Proc. pmid:12072357
Nishi K et al. The expression of intestinal CYP3A4 in the piglet model. 2004 Transplant. Proc. pmid:15050159
Platz KP et al. Immunosuppressive power and limitations of FK 506 for prevention and treatment of graft-vs-host disease after small bowel transplantation. 1996 Transplant. Proc. pmid:8907933
Coupes BM et al. Tacrolimus monotherapy in renal transplantation: four-year data. 2002 Transplant. Proc. pmid:12176506
Meçule A et al. Tacrolimus trough levels and level-to-dose ratio in stable renal transplant patients converted to a once-daily regimen. 2011 Transplant. Proc. pmid:21620042
Iaria G et al. Switch from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in kidney transplantation. 2011 Transplant. Proc. pmid:21620043
Guy S et al. Successful treatment of acute severe graft-versus-host-disease in a pancreas-after-kidney transplant recipient: case report. 2014 Transplant. Proc. pmid:25179161
Imanishi M et al. Induction of tolerance by intrathymic injection of donor bone marrow cells in the rat: simultaneous heart and skin allograft model. 1994 Transplant. Proc. pmid:7520615
Yoshimura N et al. A new immunosuppressive agent, FK506, inhibits the expression of alloantigen-activated suppressor cells as well as the induction of alloreactivity. 1989 Transplant. Proc. pmid:2468202
McCauley J et al. Renal function after conversion from cyclosporine to FK 506 in liver transplant patients. 1991 Transplant. Proc. pmid:1721387
Kaufman DB et al. Single-center experience of 60 consecutive simultaneous pancreas-kidney transplants using mycophenolate mofetil and tacrolimus as primary maintenance immunotherapy. 1999 Feb-Mar Transplant. Proc. pmid:10083261
Stratta RJ Optimal immunosuppression in pancreas transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083263
Guo Z et al. Leflunomide, a potential immunosuppressant for pancreatic islet transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123314
Walgenbach KJ et al. Immunocytes of composite tissue allografts express elevated levels of TGF beta mRNA and protein during chronic rejection. 1997 Feb-Mar Transplant. Proc. pmid:9123418
Hesse CJ et al. The value of routine monitoring of mycophenolic acid plasma levels after clinical heart transplantation. 2001 Transplant. Proc. pmid:11377487
Platz KP et al. Incidence and outcome of chronic rejection in CyA- and FK 506-treated patients. 1996 Transplant. Proc. pmid:8962235
Uchida K et al. Usefulness of monitoring of AUC(0-4h) during the induction period of immunosuppressive therapy with tacrolimus after renal transplantation. 2002 Transplant. Proc. pmid:12176556
Iwamoto H et al. Early steroid withdrawal in adult kidney transplantation at a single center. 2012 Transplant. Proc. pmid:22310609
Tzakis AG et al. FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. 1991 Transplant. Proc. pmid:1721416
Masaoka T et al. Phase II study of FK 506 for allogeneic bone marrow transplantation. 1991 Transplant. Proc. pmid:1721417
Tojimbara T et al. Cyclosporine and tacrolimus both suppress activation of Kupffer cells in vitro. 1996 Transplant. Proc. pmid:8658704
Vincenti F Tacrolimus (FK 506) in kidney transplantation: five-year survival results of the U.S. multicenter, randomized, comparative trial. 2001 Feb-Mar Transplant. Proc. pmid:11267172
Dick TB et al. Fludrocortisone is effective in the management of tacrolimus-induced hyperkalemia in liver transplant recipients. 2011 Transplant. Proc. pmid:21911143
Ash MM and Jolly PS A Case Report of the Resolution of Multiple Recalcitrant Verrucae in a Renal Transplant Recipient After a Mycophenolate Mofetil Dose Reduction. Transplant. Proc. pmid:28104140
Zhou S et al. Tacrolimus enhances the invasion potential of hepatocellular carcinoma cells and promotes lymphatic metastasis in a rat model of hepatocellular carcinoma: involvement of vascular endothelial growth factor-C. 2011 Transplant. Proc. pmid:21911157
Zucker MJ et al. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis. 2005 Transplant. Proc. pmid:15964386
Gridelli B et al. Frequency of switch from cyclosporine to FK 506 before and after Neoral use in pediatric liver transplantation. 1998 Transplant. Proc. pmid:9723311
Kiberd BA et al. Impact of mycophenolate mofetil loading on drug exposure in the early posttransplant period. 2005 Transplant. Proc. pmid:15964408
Lagget M et al. Disappearance of diabetes mellitus after conversion from FK 506 to Neoral in two liver transplanted patients. 1998 Transplant. Proc. pmid:9723312
Hummel AD et al. Application of artificial neural networks in renal transplantation: classification of nephrotoxicity and acute cellular rejection episodes. 2010 Transplant. Proc. pmid:20304167
Wiseman AC et al. Fixed-dose sirolimus with reduced dose calcineurin inhibitor: the University of Colorado experience. 2003 Transplant. Proc. pmid:12742482
Holt DW et al. Therapeutic monitoring of sirolimus: its contribution to optimal prescription. 2003 Transplant. Proc. pmid:12742490
Webb NJ et al. Pharmacokinetics of tacrolimus in paediatric renal transplant recipients. 2002 Transplant. Proc. pmid:12176639
Collin C et al. Sublingual tacrolimus as an alternative to intravenous route in patients with thoracic transplant: a retrospective study. 2010 Transplant. Proc. pmid:21168693
Sundberg AK et al. Conversion from cyclosporine to tacrolimus is preferred by pediatric renal transplant recipients: a focus on opinions and outcomes. 2002 Transplant. Proc. pmid:12176640
Li ZY et al. Analytical performance of the Abbott Architect i2000 tacrolimus assay in Chinese patients after renal transplantation. 2010 Transplant. Proc. pmid:21168731
Veroux M et al. Caspofungin in the treatment of azole-refractory esophageal candidiasis in kidney transplant recipients. 2006 Transplant. Proc. pmid:16757256
Reichenspurner H et al. First experience with FK 506 for treatment of chronic pulmonary rejection. 1995 Transplant. Proc. pmid:7540775
Markus BH et al. Daclizumab induction therapy in combination with tacrolimus. 2001 Feb-Mar Transplant. Proc. pmid:11267354
Abu-Elmagd K et al. FK 506: a new therapeutic agent for severe recalcitrant psoriasis. 1991 Transplant. Proc. pmid:1721449
Ueda D et al. Influence of FK 506 on renal blood flow. 1993 Transplant. Proc. pmid:7689280
Reiner J et al. After Intestinal Transplantation Kidney Function Is Impaired by Downregulation of Epithelial Ion Transporters in the Ileum. 2016 Transplant. Proc. pmid:27109987
Rao B et al. Use of Everolimus After Multivisceral Transplantation: A Report of Two Cases. 2016 Transplant. Proc. pmid:27109983
González MG et al. Comparison of post-liver transplantation electrocardiographic alterations between cyclosporine- and tacrolimus-treated patients. 1999 Transplant. Proc. pmid:10500652
Kinukawa T et al. Long-term comparison of tacrolimus and cyclosporine-based immunosuppression in kidney recipients with grafts from non-heart-beating cadaver donor. 1998 Transplant. Proc. pmid:9636498
Morris-Stiff G et al. Preoperative induction with tacrolimus does not have a detrimental effect on primary graft function in adult cadaveric renal transplantation. 1998 Transplant. Proc. pmid:9636499
Alak AM and Moy S Biological activity of tacrolimus (FK506) and its metabolites from whole blood of kidney transplant patients. 1997 Transplant. Proc. pmid:9270821
Scholler G et al. Comparison of cyclosporine A and FK506 with regard to complaints and psychosocial characteristics before and after liver transplantation. 1997 Transplant. Proc. pmid:9270822
Nielsen FT et al. Nephrotoxity of FK 506: a preliminary study on comparative aspects of FK 506 and cyclosporine nephrotoxicity. 1994 Transplant. Proc. pmid:7527946
Fisher A et al. Gastrointestinal toxicity associated with FK 506 in liver transplant recipients. 1994 Transplant. Proc. pmid:7527947